Oncolytic Virus Therapy Market is estimated to grow at a 24.5% CAGR during the forecast period for 2025-2034.
In recent decades, the healthcare burden of Cancer increasing rapidly with an increasing incidence rate. The massive investment in research and development has been implemented to find innovative drugs/therapy/Immuno oncology solutions to cure cancer. Some of them gaining interest include oncolytic viruses therapy, stem cell therapies, adoptive cell therapies, etc. Treatment-related off-target effects, side effects, and drug resistance hamper the efficacies of many therapeutic options. Therefore, scientists are working to develop new, effective therapies with low or no toxicity in normal cells. Oncolytic viruses therapy has shown immense opportunities and potential to be tapped in the future to enhance the cancer treatment. Immunotherapy with oncolytic viruses would definitely build survival solutions with significant importance.
The global oncolytic viruses therapy market is segmented on the basis of product, application, and region. Based on the products, the market is divided into Adenoviruses, Herpes Simplex Virus, Vesicular Stomatitis Virus, Vaccinia Virus, and Newcastle Disease Virus. On the basis of application type, the market is segmented into Breast Cancer, Prostate Cancer, Melanoma, Ovarian Cancer, and Others. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that, Europe held the largest share of the oncolytic viruses therapy market, followed by America and Asia Pacific. On the other hand, North America is expected to dominate the oncolytic viruses therapy market during the analysis of the forecast period.
| Report Attribute | Specifications |
| Growth Rate CAGR | CAGR of 24.5% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Product, By Application |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; South Korea; South East Asia |
| Competitive Landscape | Provectus Biopharmaceuticals, Inc., Takara Bio Inc., SillaJen, Inc., Oncorus, Inc., Amgen, OncoMyx Therapeutics, Inc., Replimune Inc., Oncolytics Biotech, Vyriad, Inc., Viralytics, Transgene SA, OncolysBioPharma, Unleash ImmunoOncolytics, Inc., TargovaxPsiOxus Therapeutics, Sorrento Therapeutics, Lokon Pharma AB, Genelux Corporation, TILT Biotherapeutics, Cold Genesys and Western Oncolytics. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Global Oncolytic Virus Therapy Market by Product
Global Oncolytic Virus Therapy Market by Application
Global Oncolytic Virus Therapy Market Outlook Based on Region
Europe Oncolytic Virus Therapy Market Outlook
North America Oncolytic Virus Therapy Market Outlook
Asia Pacific Oncolytic Virus Therapy Market Outlook
Latin America Oncolytic Virus Therapy Market Outlook
Middle East & Africa Oncolytic Virus Therapy Market Outlook
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Oncolytic Virus Therapy Market Snapshot
Chapter 4. Global Oncolytic Virus Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Penetration & Growth Prospect Mapping
4.6. Clinical Trial/Pipeline Analysis
4.7. Industry Analysis – Porter’s Five Forces Analysis
4.8. Competitive Landscape & Market Share Analysis
Chapter 5. Market Segmentation 1: Product Estimates & Trend Analysis
5.1. Product Type & Market Share, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Product:
5.2.1. HSV-based Oncolytic Viruses
5.2.2. Adenoviruses-based Oncolytic Viruses
5.2.3. Vaccinia Virus-based Oncolytic Viruses
5.2.4. Vesicular Stomatitis Virus-based Oncolytic Viruses
5.2.5. Newcastle Disease Virus-based Oncolytic Viruses
Chapter 6. Oncolytic Virus Therapy Market Segmentation 2: Application Estimates & Trend Analysis
6.1. Application Analysis & Market Share, 2024-2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021-2034 for the following Application:
6.2.1. Melanoma
6.2.2. Prostate Cancer
6.2.3. Breast Cancer
6.2.4. Ovarian Cancer
6.2.5. Others
Chapter 7. Oncolytic Virus Therapy Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Oncolytic Virus Therapy Market revenue (US$ Million) estimates and forecasts by product, 2021-2034
7.1.2. North America Oncolytic Virus Therapy Market revenue (US$ Million) estimates and forecasts by end-user, 2021-2034
7.1.3. North America Oncolytic Virus Therapy Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.1.3.1. U.S.
7.1.3.2. Canada
7.2. Europe
7.2.1. Europe Oncolytic Virus Therapy Market revenue (US$ Million) by product, 2021-2034
7.2.2. Europe Oncolytic Virus Therapy Market revenue (US$ Million) by end-user, 2021-2034
7.2.3. Europe Oncolytic Virus Therapy Market revenue (US$ Million) by country, 2021-2034
7.2.3.1. Germany
7.2.3.2. Poland
7.2.3.3. France
7.2.3.4. Italy
7.2.3.5. Spain
7.2.3.6. UK
7.2.3.7. Rest of Europe
7.3. Asia Pacific
7.3.1. Asia Pacific Oncolytic Virus Therapy Market revenue (US$ Million) by product, 2021-2034
7.3.2. Asia Pacific Oncolytic Virus Therapy Market revenue (US$ Million) by end-user, 2021-2034
7.3.3. Asia Pacific Oncolytic Virus Therapy Market revenue (US$ Million) by country, 2021-2034
7.3.3.1. China
7.3.3.2. India
7.3.3.3. Japan
7.3.3.4. Australia
7.3.3.5. Rest of Asia Pacific
7.4. Rest of World
7.4.1. Rest of World Oncolytic Virus Therapy Market revenue (US$ Million) by product, 2021-2034
7.4.2. Rest of World Oncolytic Virus Therapy Market revenue (US$ Million) by end-user, 2021-2034
7.4.3. Rest of World Oncolytic Virus Therapy Market revenue (US$ Million) by country, 2021-2034
7.4.3.1. Middle East
7.4.3.2. Africa
7.4.3.3. Latin America
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Provectus Biopharmaceuticals, Inc.
8.2.2. Takara Bio Inc.
8.2.3. SillaJen, Inc.
8.2.4. Oncorus, Inc.
8.2.5. Amgen
8.2.6. OncoMyx Therapeutics, Inc.
8.2.7. Replimune Inc.
8.2.8. Oncolytics Biotech
8.2.9. Vyriad, Inc.
8.2.10. Viralytics
8.2.11. Transgene SA
8.2.12. Oncolys BioPharma
8.2.13. Unleash Immuno Oncolytics, Inc.
8.2.14. Targovax
8.2.15. PsiOxus Therapeutics
8.2.16. Sorrento Therapeutics
8.2.17. Lokon Pharma AB
8.2.18. Genelux Corporation
8.2.19. TILT Biotherapeutics
8.2.20. Cold Genesys
8.2.21. Western Oncolytics